DRKS00012701招募中3 期
German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV - LCH-IV-G-2016
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- one 至 18 Years（—）
- 性别
- All
入选标准
- •Age: Patients must be less than 18 years of age at the time of enrollment.
- •No systemic therapy for LCH prior to the standardized induction therapy, e.g., prior to Initial Course 1 (IC-1) and, eventually, Initial Course 2 (IC-2) (pre-study)
- •Evaluation demonstrates non-active disease after IC-1 (independent of involvement of risk organs) or non-active disease or active disease better (only for patients without involvement of risk organs) after IC-2 [imaging studies need to be referenced regarding treatment response to initial course(s) (pre-study)]
- •Stratum II:
- •Age: Patients must be older than 2 years and less than 18 years of age at the time of enrollment
- •No systemic therapy for progression/relapse of LCH prior to the standardized second line therapy, e.g., standardized 24-week second-line initial course (SL-IT), which is NOT part of the study
- •Evaluation demonstrates non-active disease or active disease better after SL-IT [imaging studies need to be referenced regarding treatment response to second-line initial course (pre-study)].
- •Both Strata:
- •Patients must have a referenced histological verification of the diagnosis of LCH (pre-study)
- •Male subjects able to father children and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception (e.g., barrier contraception for males, contraceptive pill (Pill”) for female) throughout the study and for at least 90 days (male subjects) and 30 days (female subjects) after the last dose of assigned study treatment.
- •Signed informed consent of parent(s)/legal guardian(s) and/or patient (when applicable depending on age and patient’s compliance) prior to any protocol procedure
排除标准
- •Patients with any active disease after IC-1 or patients with active disease intermediate/worse (for patients without involvement of risk organs) or any active disease (for patients with involvement of risk organs) after IC-2
- •Hypersensitivity for one of the trial drugs or any of its excipients or hypersensitivity to any other vinca-alkaloid or any of its excipients
- •Leukopenia, which is not caused by LCH
- •Severe uncontrolled infection
- •Stomatitis or ulcera of the gastrointestinal tract
- •Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)
- •Breastfeeding
- •Participation in other clinical trials according to German drug law (§§40ff AMG)
- •Stratum II:
- •Patients with progressive disease in risk organs
- •Patients with active disease intermediate/worse after second-line intensive course
- •Hypersensitivity for one of the trial drugs or any of its excipients
- •Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy
- •Breastfeeding
- •History of severe bleeding, ulcera of the gastrointestinal tract, history of CNS bleeding or other bleeding disorders unrelated to LCH
- •Patient suffering from Crohn´s disease or Colitis ulcerosa
- •History of asthma, urticaria, or other allergic-type reactions after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs.
- •Known severe immunodeficiency, untreated blood disorders not caused by LCH or untreated functional disorders of the hematopoietic system*
- •Severe impairment of liver, chronic liver disease, increased alcohol consumption
- •Renal impairment (creatinine-clearance < 60 ml/min)
- •Heart insufficiency
- •Severe uncontrolled infection
- •Participation in other clinical trials according to German drug law (§§40ff AMG)
- •*Note: Both LCH and preceding chemotherapy for LCH, which is mandatory for the cure of the patient, may cause blood disorders/functional disorders of the hematopoietic system as well as clotting disorders. This is similar to other hematological diseases such as acute lymphoblastic leukemia, in which standard treatment consists of cytotoxic agents such methotrexate. Therefore, the inclusion of patients with blood disorders unrelated to LCH depends on the careful evaluation of the treating investigator, if the patient is in stable condition and the disorder is sufficiently treated.
研究者
相似试验
进行中（未招募）
1 期
German Treatment Optimization Study for Children with newly diagnosed and relapsed Langerhans cell Histiocytosis (LCH)angerhans cell Histiocytosis (LCH)EUCTR2016-003568-38-DEJohann Wolfgang Goethe-University Frankfurt am Main300
已完成
不适用
The evaluation of effectiveness of Cydonia oblonga syrup on clinical symptoms in patients with Gastroesophageal reflux diseasePediatric gastro-oesophageal reflux disease.Gastro-oesophageal reflux disease without oesophagitisIRCT2015030921388N1Shiraz University of Medical Sciences80
进行中（未招募）
1 期
Treatment study for children and adolescents with Acute Promyelocytic LeukemiaEUCTR2017-002383-40-ITAIEOP- Associazione Italiana Ematologia Oncologia Pediatrica90
进行中（未招募）
1 期
Treatment study for children and adolescents with Acute Promyelocytic LeukemiaEUCTR2017-002383-40-CZAIEOP- Associazione Italiana Ematologia Oncologia Pediatrica90
进行中（未招募）
1 期
Treatment study for children and adolescents with Acute Promyelocytic Leukemiaacute promyelocytic leukemia (APL) in children and adolescentsEUCTR2017-002383-40-SEAIEOP- Associazione Italiana Ematologia Oncologia Pediatrica90